Know Cancer

or
forgot password

Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result


N/A
40 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result


PCA3 is a gene that is highly over-expressed in more than 90% of prostate cancers, and that
can be quantified in urine specimens following a digital rectal examination. Studies have
shown that because PCA3 is highly specific for prostate cancer, it predicts the results of
repeat biopsies more accurately than traditional prostate-specific antigen (PSA) testing.
Gen-Probe's PROGENSA(R) PCA3 assay is the first urine-based molecular diagnostic assay for
prostate cancer.


Inclusion Criteria:



- Men 40+ years of age who have had at least 1 previous negative prostate biopsy, who
have never had a positive prostate biopsy, and who have been recommended for a repeat
biopsy by their clinician.

- The subject must be able to comprehend and sign an approved informed consent form and
other applicable study enrollment documents

Exclusion Criteria:

- Use of medications or hormones that are known to affect serum PSA levels within 3 - 6
months of study enrollment

- Clinical symptoms of urinary tract infection (including prostatitis) at the time of
enrollment

- History of prostate cancer

- History of invasive treatments for benign prostatic hypertrophy (BPH) or lower
urinary tract symptoms within 6 months of study enrollment

- Medical history or concurrent illness that the investigator considers sufficiently
serious to interfere with the conduct, completion, or results of this trial, or
constitutes an unacceptable risk to the subject

- Participation in pharmaceutical or treatment related clinical study within 6 months
of study enrollment. Exception: Trials for non-prostate conditions may be acceptable,
with approval by the investigator and Sponsor

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.)

Outcome Description:

The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score >=25 was positive, PCA3 Score <25 was negative

Outcome Time Frame:

At the time of biopsy

Safety Issue:

No

Principal Investigator

Jennifer Reid, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Gen-Probe, Incorporated

Authority:

United States: Institutional Review Board

Study ID:

2009PCA301

NCT ID:

NCT01024959

Start Date:

August 2009

Completion Date:

April 2010

Related Keywords:

  • Prostatic Neoplasms
  • Prostate Cancer
  • Prostate Biopsy
  • PCA3
  • Neoplasms
  • Prostatic Neoplasms

Name

Location

MD Anderson Cancer CenterHouston, Texas  77030-4096
Urology San Antonio ResearchSan Antonio, Texas  78229
South Florida Medical ResearchAventura, Florida  33180
AccuMed Research AssociatesGarden City, New York  11530
Healthcare Partners Medical GroupTorrance, California  90503
Columbus Urology Research, LLCColumbus, Ohio  43214
Metropolitan Urology, PSCJeffersonville, Indiana  47130
Florida Urology SpecialistsSarasota, Florida  34237
San Diego Clinical TrialsSan Diego, California  92120
Specialists in UrologyNaples, Florida  34102
Regional Urology Specialists, LLCShreveport, Louisiana  71106
TriState Urologic Services PSC Inc. dba The Urology GroupCincinnati, Ohio  45212
Virginia UrologyRichmond, Virginia  23235